Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Kingworld Medicines Group Ltd. ( (HK:1110) ) just unveiled an announcement.
Kingworld Medicines Group Limited, a distributor of imported branded pharmaceutical and healthcare products in China, also generates revenue from organizing promotion activities for these healthcare brands. The company is listed in Hong Kong and focuses on serving demand in the domestic Chinese pharmaceuticals and healthcare market.
The group expects to swing to a profit in the second half of 2025 after posting a loss of about RMB5.4 million in the first half, but full-year profit attributable to shareholders is projected to fall by roughly 70% to 75% from RMB41.6 million in 2024. Management attributes the sharp decline mainly to a 15%–20% drop in gross profit from imported product distribution due to weaker market demand and a 40%–45% fall in promotion fee income caused by fewer promotional events, signaling pressure on its core operations and revenue streams.
The most recent analyst rating on (HK:1110) stock is a Hold with a HK$0.59 price target. To see the full list of analyst forecasts on Kingworld Medicines Group Ltd. stock, see the HK:1110 Stock Forecast page.
More about Kingworld Medicines Group Ltd.
Kingworld Medicines Group Limited is a Hong Kong-listed company engaged in the distribution of imported branded pharmaceutical and healthcare products in China. The group also derives income from promotion services, organizing marketing and promotional events for its healthcare product portfolio within the Chinese market.
Average Trading Volume: 972,982
Technical Sentiment Signal: Sell
Current Market Cap: HK$303.2M
Learn more about 1110 stock on TipRanks’ Stock Analysis page.